{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:53:20Z","timestamp":1784836400439,"version":"3.55.0"},"reference-count":6,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to evaluate the HIV virological efficacy of two\u2010drug regimens (2DR) with lamivudine (3TC) and dolutegravir (DTG) in people with HIV (PWH), classified by their hepatitis B virus (HBV) serological status. Specifically, it explored whether isolated anti\u2010hepatitis B core (anti\u2010HBc) positivity impacts virological outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective observational study was conducted at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, enrolling 606 virologically suppressed (HIV\u2010RNA\u2009&lt;\u200950 copies\/mL) PWH who switched to a 2DR regimen with 3TC\/DTG. Participants were categorized into four groups based on their HBV serological status: hepatitis B surface antibody (HBsAb)\u2010positive\/hepatitis B core antibody (HBcAb)\u2010positive, HBsAb\u2010negative\/HBcAb\u2010negative, HBsAb\u2010positive\/HBcAb\u2010negative, and isolated HBcAb positivity. Viral failure (VF) was defined as two consecutive HIV viral loads above 50 copies\/mL or a single HIV viral load above 1000 copies\/mL, and viral blips (VBs) as a single HIV\u2010RNA measurement between 50 and 200 copies\/mL followed by suppression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During 2216.4 patient\u2010years of follow\u2010up (PYFU), we observed 30 VFs (1.3 per 100 PYFU) and 63 VBs (2.9 per 100 PYFU). No statistically significant differences in VF or VB were noted between the serological groups. Additionally, no significant alanine aminotransferase (ALT) flares or HBV\u2010DNA breakthroughs were observed, with HBV\u2010DNA remaining undetectable throughout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study supports the virological efficacy of 3TC\/DTG\u2010based 2DR in PWH, regardless of HBV serological status. Isolated anti\u2010HBc positivity did not influence virological outcomes independently. Larger studies are warranted to further investigate HIV\u2013HBV interactions in this context.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13765","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:20:01Z","timestamp":1738754401000},"page":"650-653","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of <scp>HBV<\/scp> serological status on <scp>HIV<\/scp> virological efficacy of two\u2010drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with <scp>HIV<\/scp> switching to lamivudine\/dolutegravir"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7559-7364","authenticated-orcid":false,"given":"Pierluigi Francesco","family":"Salvo","sequence":"first","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5941-883X","authenticated-orcid":false,"given":"Arturo","family":"Ciccullo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, San Salvatore Hospital  L'Aquila Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Visconti","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive Fondazione Policlinico Universitario \u201cAgostino Gemelli\u201d, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-8346","authenticated-orcid":false,"given":"Francesca","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive Fondazione Policlinico Universitario \u201cAgostino Gemelli\u201d, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive Fondazione Policlinico Universitario \u201cAgostino Gemelli\u201d, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"Dipartimento di Sicurezza e Bioetica \u2013 Sezione di Malattie Infettive Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"},{"name":"Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive Fondazione Policlinico Universitario \u201cAgostino Gemelli\u201d, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive Fondazione Policlinico Universitario \u201cAgostino Gemelli\u201d, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"EACS Guidelines version 12.0 October 2023. Available at:https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812103392413"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010202"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16030348"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac036"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa313"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T15:43:17Z","timestamp":1743867797000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/hiv.13765"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13765","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"2024-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}